Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

31.5%

46 terminated/withdrawn out of 146 trials

Success Rate

66.4%

-20.1% vs industry average

Late-Stage Pipeline

31%

45 trials in Phase 3/4

Results Transparency

86%

78 of 91 completed trials have results

Key Signals

3 recruiting78 with results40 terminated6 withdrawn

Enrollment Performance

Analytics

Phase 2

49(38.3%)

Phase 1

28(21.9%)

Phase 3

27(21.1%)

Phase 4

18(14.1%)

N/A

4(3.1%)

Early Phase 1

2(1.6%)

128Total

Phase 2(49)

Phase 1(28)

Phase 3(27)

Phase 4(18)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (146)

Showing 20 of 146 trials

NCT03271372Phase 3Active Not Recruiting

Adjuvant Avelumab in Merkel Cell Cancer

Role: collaborator

NCT06110195Phase 1Terminated

Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer

Role: collaborator

NCT04004442Phase 1Active Not Recruiting

Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

Role: collaborator

NCT07225660Not ApplicableRecruiting

Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)

Role: collaborator

NCT06138561Recruiting

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

Role: collaborator

NCT06518564Phase 2Recruiting

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

Role: collaborator

NCT04178005Phase 4Active Not Recruiting

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

Role: collaborator

NCT03747419Phase 2Terminated

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Role: collaborator

NCT03091374Phase 2Completed

Impact of Recombinant Human Growth Hormone on HIV Persistence

Role: collaborator

NCT04792073Phase 2Active Not Recruiting

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

Role: collaborator

NCT04539002Phase 1Completed

Aerobic Exercise for Remyelination in Multiple Sclerosis

Role: collaborator

NCT03737721Phase 2Terminated

The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy

Role: collaborator

NCT03357757Phase 2Completed

Avelumab With Valproic Acid in Virus-associated Cancer

Role: collaborator

NCT03963375Phase 4Completed

Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis

Role: collaborator

NCT02093962Phase 2Terminated

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Role: collaborator

NCT04754542Completed

Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study

Role: collaborator

NCT06068634Completed

Patient-Centered Care Survey

Role: collaborator

NCT03770455Phase 2Terminated

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Role: collaborator

NCT03200587Phase 1Completed

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

Role: collaborator

NCT03892642Phase 1Completed

Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer

Role: collaborator